Total Funding
27
62
Total FundingSeed raised
Growth Score
-6 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
138295
NVector is a company that specializes in biomarker development, diagnostics, and AAV (adeno-associated virus) gene therapy.
Robert Bowser Ph.D.: FounderPast Role: Knopp Biosciences, Founder- Fredric Manfresson Ph.D.: Chief Scientific Officer
About the Company
nVector's next-generation gene therapy technology is positioned to enable groundbreaking treatments for central nervous system (CNS) diseases, including Alzheimer's, Parkinson's, ALS, and traumatic brain injury. The company integrates its AAV program with a biomarker testing platform and assay development. nVector's AAV platform
is distinguished as the first technology capable of targeting brain glia (immune) and neuron cells by type, providing enhanced distribution throughout the spinal cord and brain with a single injection. The company's flagship capsid, nCap-001, has been validated and is prepared for market introduction.
